Promega in collaboration to advance drug discovery methods
US-based Promega Corporation has entered into a collaboration agreement with the Guangzhou Institute of Biomedicine and Health (GIBH), Chinese Academy of Sciences, to co-develop compound profiling solutions for small molecule and traditional Chinese medicine drug screening.
US-based Promega Corporation has entered into a collaboration agreement with the Guangzhou Institute of Biomedicine and Health (GIBH), Chinese Academy of Sciences, to co-develop compound profiling solutions for small molecule and traditional Chinese medicine drug screening.
By combing the drug discovery expertise of GIBH with the biological assay expertise of Promega, the partnership is intended to deliver turnkey services to pharmaceutical companies interested in speeding up their lead discovery and lead optimisation processes.
Guangzhou Institute of Biomedicine and Health (GIBH), Chinese Academy of Sciences, is the first integrated research organisation that focuses on translational research and drug discovery in China. It has four disease-focused research areas: infectious diseases, cancers, metabolic diseases and cardiovascular Diseases. Recently, the institute has launched a new research centrr for regenerative medicine and stem cell.
GIBH scientists will offer contract services designed to profile the biology of potential leads using the Promega suite of biological drug screening assays. Initial plans call for development of cytochrome P450, cytotoxicity, kinase and GPCR profiling assays. GIBH will use the assays both in house for own discovery programmes as well as offer them on a contract basis to outside companies.